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Abstract
Chromatin modification (CM) plays a key role in regulating transcription, DNA replication, repair and recombination.
However, our knowledge of these processes in humans remains very limited. Here we use computational approaches to
study proteins and functional domains involved in CM in humans. We analyze the abundance and the pair-wise domain-
domain co-occurrences of 25 well-documented CM domains in 5 model organisms: yeast, worm, fly, mouse and human.
Results show that domains involved in histone methylation, DNA methylation, and histone variants are remarkably
expanded in metazoan, reflecting the increased demand for cell type-specific gene regulation. We find that CM domains
tend to co-occur with a limited number of partner domains and are hence not promiscuous. This property is exploited to
identify 47 potentially novel CM domains, including 24 DNA-binding domains, whose role in CM has received little attention
so far. Lastly, we use a consensus Machine Learning approach to predict 379 novel CM genes (coding for 329 proteins) in
humans based on domain compositions. Several of these predictions are supported by very recent experimental studies and
others are slated for experimental verification. Identification of novel CM genes and domains in humans will aid our
understanding of fundamental epigenetic processes that are important for stem cell differentiation and cancer biology.
Information on all the candidate CM domains and genes reported here is publicly available.
Citation: Pu S, Turinsky AL, Vlasblom J, On T, Xiong X, et al. (2010) Expanding the Landscape of Chromatin Modification (CM)-Related Functional Domains and
Genes in Human. PLoS ONE 5(11): e14122. doi:10.1371/journal.pone.0014122
Editor: Tim J. Hubbard, Wellcome Trust Sanger Institute, United Kingdom
Received May 4, 2010; Accepted October 26, 2010; Published November 29, 2010
Copyright:  2010 Pu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by a grant from the Canadian Institutes of Health Research (CIHR TEAM Grant #82940). S.J.W. is a Tier 1 Canada Research Chair in
Computational Biology and Bioinformatics and acknowledges support from the Canadian Institutes for Health Research, the Hospital for Sick Children and the
Sickkids Foundation, Toronto, Canada. J.G. acknowledges support from Ontario Genomics Institute and Genome Canada. J.P. is supported by a CIHR New
Investigators award and an Early Researcher award from the Ontario Ministry of Research and Innovation. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: shoshana@sickkids.ca
Introduction
Chromatin modification (CM) encompasses chromatin remodel-
ing (eviction, deposition, or sliding of nucleosomes along DNA),
histone exchange (substitutionof core histoneswithhistone variants)
and covalent modification of DNA (methylation) and histones
(acetylation, methylation, ubiquitylation, phosphorylation, etc.). By
altering chromatin structure globally (e.g., chromatin condensation
and heterochromatin formation) and locally (e.g., mobilization of
nucleosomes), CM dictates access to DNA, thereby playing vital
roles in the regulation of all DNA-templated processes, such as
transcription and DNA recombination, replication, and repair [1].
For instance, post-translational modifications of histones, one of the
many forms of CM, are crucial for the regulation of gene activity.
Specifically, histone hyperacetylation is positively correlated with
actively transcribed genes [2]. Tri-methylation of H3K4
(H3K4me3) or H3K36 (H3K36me3) is associated with gene
activation [1], while H3K9me3 or H3K27me3 is associated with
transcriptional repression and heterochromatin formation [3]. In
embryonic stem cells, co-existence of both H3K4me3 and
H3K27me3 in promoter regions marks key developmental genes
that are in poised states [4,5].
CM has been most extensively studied in the budding yeast, a
simple unicellular eukaryote that is amenable to experimental
manipulations. However, our knowledge of these processes in
human remains very limited. This situation is illustrated by the
paucity of genes annotated as CM-related for human as compared
to the yeast in the Gene Ontology (GO) database [6]. For yeast, 230
genes are associated with CM in the GO hierarchy on the basis of
directexperimental evidence.The correspondingnumberofhuman
genes is only 77 (Figure 1). Including yeast and human genes coding
for components of CM-related protein complexes [7,8] and other
genes derived by curating the recent literature (See Materials and
Methods for detail), expands the list of yeast CM genes to a total of
312 members, whereas the expanded list of human CM genes does
not exceed 398. This latter number is comparatively small,
considering the ,3-fold larger size of the human genome and the
existence in human of more than 200 distinct cell types. Hence,
many more CM-related genes remain to be discovered in humans.
In this study we use computational methods to identify new
proteins (genes) and domains within proteins, with CM-related
function in the human genome. These methods exploit informa-
tion on protein domains, both CM-related and others, currently
annotated by the Pfam database [9].
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chromatin modifying factors exhibit distinct protein domains that
perform specific functions, such as the SET domain (a catalytic
domain of many histone lysine methyltransferases), Bromodomain
(responsible for recognition of acetylated histone lysine) and
Chromodomain (responsible for binding of methylated histone
lysine) [10,11]. In fact, the majority of eukaryotic proteins contain
domains that carry out specific functions (not necessarily CM
related) and have independent evolutionary histories [12,13]. The
different types of domains in a protein - its domain composition -
and even more so, the arrangements of these domains along the
polypeptide sequence, - the domain architecture - reveal a great
deal about the protein’s functions [14,15]. Even a simple measure
such as domain composition has been very informative in this
regard. Proteins with the same domain composition are often
evolutionarily related and have the same or similar functions [12].
This observation has been exploited to predict protein function
[16], cellular localization [17] and protein-protein interactions
[18,19].
Here, we analyze respectively, the abundance and the pair-wise
domain-domain co-occurrences of 25 domains found in well-
documented CM proteins in 5 model organisms: the yeast
Saccharomyces cerevisiae, the worm Caenorhabditis elegans, the fly
Drosophila melanogaster, the mouse Mus musculus and the human
Homo sapiens. This analysis allows us to evaluate the relative
enrichment of known CM domain families between different
organisms and to estimate the promiscuity of CM domains, or the
degree to which they tend to co-occur with different domains across
proteins in a genome. Furthermore, computing the propensity of
domains to co-occur with known CM domains enables us to
annotate 47 additional domains with CM-related functions.
In the final part of our study, we use a consensus Machine
Learning approach based on the popular support vector machine
(SVM) technique [20], to identify 379 novel candidate CM genes
in human on the basis of the domain compositions of known CM
genes in yeast and human.
We show that our domain-based analysis produces richer, and
by and large complementary, information to function predictions
based on orthology relationships [21], and that it yields new
insights on how domains contribute to building complexity in CM
function in higher eukaryotes.
Materials and Methods
Data on genes and domains
Protein-coding genes from yeast, worm, fly, mouse and human,
as well as their Pfam A domain compositions [9], were obtained
from the Ensembl database [22] version 53 using the BioMart web
search tools (December 19, 2008). Pfam B domains were not
considered. The number of genes and unique Pfam domains in
each of the 5 model organisms is summarized in the Supplemen-
tary Table S1.
Function annotations [6] for yeast and human genes were
downloaded from the Gene Ontology (GO) databse [6] on
December 8, 2008. Yeast protein complexes were retrieved from
CYC2008, an updated archive of Curated Yeast Complexes [7].
Human protein complexes were obtained from the CORUM
(Comprehensive Resource of Mammalian protein complexes)
database [8] on January 19, 2009.
Datasets of experimentally verified CM genes
CM genes in S. cerevisiae. A list of 230 S. cerevisiae genes
annotated with ‘‘chromatin modification’’ or its child terms was
obtained from the Gene Ontology database [6]. We consider
‘‘chromatin silencing’’ as a child term of ‘‘chromatin modification’’
even though they were not linked in the GO hierarchy. This list
only included genes with the following GO evidence codes: IDA
(inferred from direct assay), IPI (inferred from protein interaction),
IGI (inferred from genetic interaction), and IMP (inferred from
mutant phenotype).
In addition, 248 genes were retrieved from 60 CM-related
complexes that are supported by experimental evidence and
archived in the CYC2008 database [7]. The two datasets were
combined to yield a consolidated list of 312 experimentally verified
yeast CM genes (Figure 1 and Supplementary Table S2).
CM genes in human. Experimentally verified human CM
genes were obtained from three sources. One is the GO database,
from which 217 human genes annotated with ‘Chromatin
Figure 1. Venn diagrams illustrating the overlap between experimentally characterized CM genes from various data sources in
yeast and human. Numbers in parentheses denote the number of genes. Refer to the text for the detailed sources of the genes in each set.
doi:10.1371/journal.pone.0014122.g001
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Filtering for genes annotated on the basis of experimental evidence
only, as described above, reduced the list to 77 genes. In addition,
we collected 308 genes from 125 human complexes archived in the
CORUM database [8]. These complexes are annotated with the
Funcat term ‘DNA conformation modification (e.g. chromatin)’,
which is equivalent to the ‘Chromatin modification’ term in the
GO [8]. Third, 138 genes encoding chromatin modification
factors or histone modifying enzymes were extracted from the
recent literature [23,24]. Figure 1 illustrates the overlap among the
genes retrieved from the three sources and the complete list is
provided in the Supplementary Table S3.
Selection of known CM domains
A list of 25 known CM domains was compiled from a survey of
the recent literature [3,10,11,23] (Table 1). This list includes 8
catalytic domains of histone modifying enzymes responsible for
histone methylation, demethylation, acetylation and deacetylation.
It also includes 9 histone modification recognition domains, a
catalytic domain of DNA methyltransferases, and 7 DNA-binding
domains.
As this study aims at identifying additional CM genes and
domains on the basis of known examples, as defined in the Pfam
classification, the list of examples was limited to protein domains
annotated as most specialized in histone or DNA modification.
Hence, many other domains found not only in histone-modifying
proteins but also in a large number of proteins involved in other
processes, were not considered. Examples of excluded domains are
those found in histone modifying kinases, ubiquitin ligases,
deiminases, prolyl isomerases and endopeptidases. For instance,
we did not utilize Methyltransf_11 (PF08241), a catalytic domain of
methyltransferases, occurring in 28 human proteins, of which only
4 are histone arginine methyltransferase. Other examples of
excluded domains are: zf-C4HC4 (PF00097) found in histone E3
ubiquitin ligase, PARP (PF00644) in histone Poly(ADP-ribose)
polymerase, and WD40 (PF00400) in some histone tail binding
proteins.
Simulation of pair-wise domain combinations in model
organisms
With the goal of identifying statistically significant domain pairs
occurring in CM proteins, the following approach was used. For
each domain pair (not necessarily adjacent to each other in the
protein sequence), we counted the number of proteins in which
this pair occurs and empirically estimated the probability of
observing this pair by chance. This was done separately for each of
the 5 model organisms considered in this study.
Estimation of the background co-occurrence probability was
performed using a simulation procedure that involves domain-pair
duplication [25]. In applying this procedure to a given genome,
Table 1. Selected known CM domains.
Pfam_Acc Pfam_id Function
PF00856 SET Protein lysine methyltransferase activity
PF08123 DOT1 H3K79 methyltransferase activity
PF02373 JmjC Histone demethylase activity [64,65,66]
PF02375 JmjN Together with JmjC, appears histone demethylase
PF00628 PHD Methylated or unmethylated histone H3 binding
PF00385 Chromo Methylated histone H3 binding [67,68]
PF00567 TUDOR Methylated histone binding [69,70,71]
PF00855 PWWP H4K20me binding [72]
PF02820 MBT Methylated histone binding [73,74]
PF01853 MOZ_SAS Histone acetyltransferase activity
PF00583 Acetyltransf_1 Acetyltransferase activity, GNAT family
PF00850 Hist_deacetyl Histone deacetylase activity
PF02146 SIR2 NAD-dependent histone deacetylase activity
PF00439 Bromodomain Acetylated histone H3, H4 binding [36,75]
PF03366 YEATS Putative histone binding domain [43]
PF01426 BAH H3, H4 tail binding [76,77]
PF00533 BRCT Phosphorylated H2A binding [44,78]
PF00145 DNA_methylase DNA-binding, DNA methylase activity
PF01429 MBD Methylated DNA-binding [45]
PF00271 Helicase_C ATP binding, helicase activity, nucleic acid binding
PF00176 SNF2_N DNA-binding, ATP binding
PF00249 Myb_DNA-binding DNA-binding
PF04433 SWIRM DNA-binding [79,80]
PF00125 Histone DNA-binding
PF00538 Linker_histone DNA-binding
A total of 25 Pfam domains occurring in well-documented CM proteins were selected as known CM domains (See the text for details). Function annotations of domains
were obtained from the Pfam database whenever available, or from the literature, otherwise. Numbers in parenthesis denote literature references.
doi:10.1371/journal.pone.0014122.t001
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particular domain), the total number of proteins and their size, in
terms of the number of distinct domains they contain, were all
maintained. Multiple copies of the same domain in a protein were
considered as one instance.
Subject to these constraints, domains were randomly shuffled
among proteins in a genome following the published procedure
[25]. Briefly, at each step, a randomly picked domain was assigned
to a randomly picked protein until all domains were assigned to
proteins. Whenever a domain pair appeared in a protein, this pair
was immediately duplicated, subject to the availabilities of the
particular domains and multi-domain proteins in the correspond-
ing genome at any given iteration, and the duplicate pair was
assigned to a different randomly chosen multi-domain protein.
This random shuffling was performed 10,000 times.
The main role of the duplication step is to improve the
correspondence between data on observed domain neighborhood
size and domain abundance in genomes, with those derived from
the random shuffling procedure [25] (Supplementary Figure S1).
For a pair of distinct domains i and j (i?j), let Aij be the observed
co-occurrence (number of genes containing this pair) in a given
genome, and Sij be the co-occurrence in a randomly shuffled
genome. Let Pij be the fraction of cases satisfying Sij$Aij in all
simulations. For example, if Aij=12, and Sij$12 occurs in 3 out of
10,000 simulation runs, then Pij=3/10000=0.0003. The co-
occurrence score (CS) for this pair of domains is then defined as:
CS(i,j)~{log(Pij)
The CS score measures how likely it is that Aij occurs by chance.
The greater the CS score, the less likely Aij occurs by chance, and
thus the more statistically significant Aij is.
The same random domain shuffling and duplication model was
also used to estimate the level of domain promiscuity. To that end
we computed for each domain 1) the size of the actual domain
‘neighborhood’ defined as the number of partner domains with
which it co-occurs in different proteins in a given genome (Ap), 2)
the neighborhood size in the random model, defined as the
number of partner domains with which it co-occurs in the
simulations (Sp), and 3) the empirical probability P=prob (Sp#Ap),
of observing neighborhood sizes smaller than Ap in the random
model. A low P value means that the observed number of partner
domains is smaller than in most instances of the simulated genome,
indicating in turn that the domain selectively combines with
limited number of other domains.
Identification of candidate CM domains based on co-
occurrence
With the goal of using information on domain co-occurrence in
order to identify candidate CM domains, we used a graph-based
procedure. A weighted graph of domain co-occurrence was
constructed for each considered organism. In this graph nodes
represent Pfam domains, and two nodes are linked by an edge if
they co-occur in a protein, regardless of the distance between them
along the protein sequence. Each edge was assigned a weight equal
to CS, the pair-wise domain co-occurrence score defined above.
Furthermore, each graph node was assigned to one of two
categories: CM nodes (representing known CM domains) and non-
CM nodes (representing non-CM domains).
Given a node n, let N
+ and N
2 represent the sets of CM nodes
and non-CM nodes connected to it respectively. An affinity score,
AS(n), for this node was computed as the fraction of total CS scores
associated with CM domain pairs over all domain pairs, counted
by linking the node to its first neighbors:
AS(n)~
P
nz(Nz
CS(n,nz)
P
nz(Nz
CS(n,nz)z
P
n{(N{
CS(n,n{)
A domain was considered as a candidate CM domain if
AS(n).0.5.
Prediction of CM genes on the basis of their domain
composition
Human genes involved in CM processes were predicted on the
basis of their domain compositions using a consensus Machine
Learning approach based on the Support Vector Machine (SVM)
classifier.
The SVM was trained on a reference set composed of positive
and negative examples consisting, respectively, of CM genes and
non-CM genes.
To have a large enough reference set, we built it from the
20,647 genes in both yeast (S. cerevisiae) and human, which contain
at least one Pfam domain. CM genes from the other model
organisms were not considered because the number of experi-
mentally verified CM genes in these organisms is too small.
The set of positive examples comprised all yeast and human
experimentally verified CM genes (see above) that contain at least
one Pfam domain, totaling 594 genes (235 from yeast and 359
from human). Defining the set of negative examples (here, non-
CM genes from both yeast and human) is a more difficult problem
[26]. A common practice is to define such a set as a random
sample from the larger set of genes that are currently not among
the positive examples [26]. However, this is unsatisfactory because
such random samples are likely to be ‘contaminated’ with CM
genes yet to be discovered. To correct for this bias, multiple
random sampling was combined with a consensus classification
strategy, as described below.
SVM classification. The domain composition of each gene
was represented as a vector Xi={x ij}
d, where the dimension
d=3831, the total number of unique Pfam domains in human and
yeast genomes; and the components xij=1 if gene i contains
domain j, otherwise xij=0. Xi was used as the predictor variables
(features) for the SVM classifier.
The SVMs were trained with the SVM_light software [27]
using a Gaussian radial basis function kernel (K(Xi, Xj)=exp
(2cIXi2XjI
2) with default C values (trade-off between training
error and margin width). The values of c (=0.1) in the above
equation and the Cost parameter (which controls the relative
weight of training errors on positive examples compared to those
on negative examples, and ranges from 3 to 5 depending on the
training sample) were determined using a grid-search strategy. The
larger Cost values (.2) ensured that training errors on positive
examples would outweigh those on the negative examples, as the
latter out-numbered the former by a ratio of 17/1.
Since human CM genes are not well annotated, it was not
possible to evaluate the performance of the classifier against an
independent dataset. We therefore used a Leave-One-Out (LOO)
cross validation, widely accepted as a valid performance test in
cases where an independent test set is not available [17].
Performance was measured in terms of the Precision, Recall, F-
measure and Accuracy, criteria as detailed in Table 2. Not too
surprisingly, we see that the performance level is moderate to low
(with Precision, Recall and F-measures ranging between 0.54–0.56
for the LOO). We believe that is due to biases in the training
dataset. Indeed, owing to the paucity of genes annotated with CM
Chromatin Modification
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used for both training and testing is most likely ‘contaminated’
with CM proteins yet to be discovered. This leads to frequent
misclassifications, because these contaminant genes will be
classified together with known CM genes, and hence be labeled
as false positives by the classifier.
False positives may also arise in cases where domains from the
same Pfam family are associated with different cellular functions.
For instance, some ‘Actin’ domain-containing cytoskeleton
proteins that seem to be unrelated to CM are misclassified as
CM proteins, most likely due to the fact that ‘Actin’ domains also
frequently appear in CM proteins in both yeast and human. In
such cases, additional knowledge, or further classification of the
domains into sub-families [28], is required to differentiate between
CM proteins containing ‘Actin’ domains, and genuine false
positives due to ‘‘contaminations’’ coming from the negative
training sets.
Consensus prediction. To correct for the above-mentioned
biases a consensus classification strategy was employed. Genes that
are not currently labeled as CM genes were randomly partitioned
into two equally sized sets of ‘unknown’ genes. The SVM classifier
was then trained using the set of known CM genes as positive
examples and one of the ‘unknown’ partitions as negative
examples. Genes in the other ‘unknown’ partition were classified
using the model obtained with the current training sets. This
process was repeated 400 times, with each unknown gene classified
approximately 200 times. Only genes classified as CM genes in
more than 95% of the repetitions were considered as candidate
CM genes. This stringent requirement eliminated 77 genes (17%
of all predictions) that are likely to be false positive. For instance,
FRAP1, which is a kinase subunit of both mTORC1 and
mTORC2 and shares domains with 3 known CM genes, was
excluded due to the fact that it was only classified as positive in
93% repetitions although it scored relatively high (0.98) by the
SVM classifier.
Ranking domains based on their relative enrichment in
human CM genes
The enrichment of Pfam domains in human CM genes was
estimated from the log odds ratio (LOR), computed for each
domain d:
LOR(d)~log(
P(dDCM)  (1{P(dDnon CM))
P(dDnon{CM)  (1{P(dDCM)))
where P(d|CM) and P(d|non-CM) are the conditional probabilities
of observing domain d given a CM gene and a non-CM gene,
respectively. In cases where P(d|CM) or P(d|non-CM) equals 0, a
background distribution was assumed, taken as 1/(CM+non_CM).
LOR(d).0 indicates that d is relatively enriched in CM genes.
LOR(d) was computed for all Pfam domains in CM and non-
CM genes in human. The extended set of CM-genes totaled 921
members and comprised the 398 experimentally verified CM
genes, 379 candidate CM genes inferred by our SVM procedure,
121 CM genes predicted on the basis of orthology relationships
reported in a recent study [21] and 23 annotated electronically by
the GO database. The remaining 20495 human genes were taken
to represent non-CM genes. All Pfam domains in human were
ranked in order of decreasing LOR(d) value.
Results
Differential expansion of CM domain families across
model organisms
The fold increase, relative to the yeast S. cerevisiae, of the number
of genes containing each of the 25 CM-specific domains
considered here is plotted in Figure 2 for 4 model organisms
(worm, fly, mouse and human). This plot confirms that domains
involved in carrying out all basic forms of post-translational
covalent histone modifications are conserved from yeast through
human and expanded in most cases, generally reflecting the size
and complexity of the genomes involved [29,30,31,32]. This
reflects the fact that histone modifications, such as lysine
acetylation/deacetylation and lysine and arginine methylation/
demethylation, carried out in the unicellular budding yeast are
conserved in metazoans, from fly to human [23].
Interestingly, our analysis reveals that domains required for
histone acetylation (Acetyltransf_1 and MOZ_SAS) and deacety-
lation (Hist_deactyl and Sir2) are only slightly expanded in the
human genome (1.5,2.2 fold over yeast). On the other hand, the
SET family (responsible for all mono-, di- and tri-methylation of
various lysine residuals in the N-terminal tail of H3 and H4 (other
than H3K79) exhibits a nearly five-fold expansion in human.
A similar trend in differential expansion is observed for domains
recognizing histone acetylation marks and methylation marks in
agreement with previous observations [33,34,35,36]. Indeed, we
find that while the Bromodomain family that binds to acetylated
lysine residues is moderately expanded (4 times in comparison to
yeast), the variety and the number of protein domains that
recognize histone methylation marks are remarkably increased in
human (PHD domain: 5 times; the royal family domains (Chromo,
TUDOR, PWWP and MBT): 9,14 times; with the MBT domain
absent in yeast). These striking expansions in domains responsible
for writing/erasing/reading of histone methylation marks in
metazoans likely reflect the greater need for gene repression that
is essential for development and tissue-specific gene regulation
[37].
Our analysis also reveals that whereas the core histones are well
conserved [38], a substantial increase in histone variants and other
Histone/Linker_histone domain-containing proteins is evident in
higher eukaryotes (7,12 times over yeast). Particularly noteworthy
is the 24-fold increase in the number of Linker_histone domain-
containing genes in the fly relative to yeast. Our gene-based
analysis may have overestimated the expansion of core histones
(H2A, H2B, H3, H4) and linker histones (H1/H5), given that the
replication-dependent core histones and linker histones are often
encoded by multiple genes [39]. However, there is ample evidence
that human and mouse have more than nine types of replication-
independent histone variants in comparison to just one (H2A.Z) in
Table 2. Performance of SVM classifiers.
Precision Recall F-measure Accuracy
Leave-one-out 0.5424 0.5646 0.5528 0.9489
Re-substitution 0.6539 0.7470 0.6967 0.9636
Re-substitution test examines self-consistency of the classification method by
classifying on the training set. Precision=TP/(TP+FP), Recall=TP/(TP+FN), F-
measure=26(Precision6Recall)/(Precision+Recall), Accuracy=(TP+TN)/
(TP+FP+TN+FN), where TP=true positive, TN=true negative, FP=false positive,
and FN=false negative. The F-measure [81] is the harmonic mean of Precision
and Recall, and is a particularly useful performance measure when the dataset is
unbalanced such that there are significantly more negative examples than
positive ones. We chose not to measure Specificity (=TN/(TN+FP)) because it is
less meaningful in such situations.
doi:10.1371/journal.pone.0014122.t002
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in mammals [40,41].
In contrast to these substantial expansions, the catalytic domains
of ATP-dependent chromatin remodeling enzymes (SNF2_N,
Helicase_C) are well conserved [42] and only moderately
expanded. This is also the case for YEATS (a putative histone
binding domain) [43], BRCT (a histone phosphorylation mark-
recognizing domain) [44], Myb_DNA_binding and SWIRM
domains (DNA-binding domains).
An important evolutionary event in chromatin-based processes
is the emergence in higher eukaryotes of DNA methylation and
related domains (DNA_methylase domain for catalysis and MBD
domain for methylated DNA-binding) [45,46]. We find, indeed,
that the number of MBD domain-containing proteins in mouse
and human is twice that in fly.
Co-occurrence of CM domains with other domains
We evaluate the propensity of two domains to co-occur in
proteins of a given genome by computing their co-occurrence
score CS which ranges from 0 to 9.9. This analysis was performed
for all domain pairs where at least one member of the pair was one
of the 25 known CM domains considered in this study.
Results presented in Figure 3 illustrate the propensity of one of
the domains, the SET domain, to co-occur with other domains in
the 5 model organisms analyzed here. Its highest scoring partner is
the Pre-SET domain in all these organisms except in yeast (which
lacks the Pre-SET domain). Two other highly scoring partner-
ships, also conserved from worm to human, are with two DNA-
binding domains FYRN and FYRC.
Figure 4 depicts the domain co-occurrence network involving
the CM domains and their co-occurring partner domains in
human. Nodes represent individual domains, and the edges, whose
thickness is proportional to the CS score, represent co-occurrence
relationships in the same genes/proteins. It appears that most CM
domains (except for SIR2, Hist_deacetyl and YEATS) tend to co-
occur with each other or share a co-occurrence partner with at
least one other CM domain. CM domains also co-occur with
many non-CM domains. In fact, some non-CM domains exhibit a
high co-occurrence score (CS) with several CM domains,
suggesting that these non-CM domains may be involved in
chromatin modification as well. Equivalent domain co-occurrence
networks for 3 other model organisms are presented in the
Supplementary Figure S2.
Prediction of candidate CM domains on the basis of
domain co-occurrence
It is reasonable to assume that domains with a high propensity
to co-occur with known CM domains may also have CM-related
functions. To identify such domains we defined an affinity score
(AS), which measures the preference of a domain to co-occur with
CM domains relative to non-CM domains. If a domain currently
classified as non-CM has a higher affinity for CM domains than
for other domains, this domain is inferred to have CM function.
Based on this analysis, we identified 47 candidate CM domains
(Table 3). Interestingly, we find that 24 of these domains are
known or putative DNA/nucleic acid-binding domains (Table 3).
Some of them are DNA-binding zinc finger domains (zf-C2H2, zf-
CXXC, zf-C2HC, zf-C5HC2 and GATA) that are frequently
found in transcription factors. While a few of these DNA-binding
domains have been shown to bind specific DNA motifs (ARID,
SAND and CBFD_NFYB_HMF), such information is lacking for
most of them. Consistent with their role in chromatin modification
proposed here, many of these DNA-binding domains appear
frequently in chromatin-associated proteins (zf-CXXC, FYRN,
FYRC, SAND, CHDCT2, CHDNT, etc.). Another 8 of the 47
candidate CM domains are known or putative protein-protein
Figure 2. Expansion in the number of known CM domains in 4 model organisms relative to that in yeast. On the X-axis, figures in
parentheses following each domain denote the numbers of genes in yeast. Y-axis represents folds of increase over yeast when the number of
domain-containing genes is non-zero in yeast, otherwise (for MBT, MBD and DNA_methylase domains), the absolute number of domain-containing
genes in each organism.
doi:10.1371/journal.pone.0014122.g002
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function of 4 candidate CM domains (BRK, Sp100, DUF1086
and DUF1087) is currently unknown.
CM domains are not promiscuous
Domain promiscuity can be defined as a high propensity of a
domain to be associated with various domains in different proteins
[47]. However, abundant domains are more likely to participate in
diverse domain architecture than their less abundant counterparts
due to chance events alone [13,25]. Therefore, to estimate the
level of promiscuity of a given domain it is necessary to factor out
the influence of domain abundance. This was done here by
measuring the extent to which the neighborhood size of a given
domain observed in a genome deviates from its neighborhood size
in our simulated random model. In both cases, the neighborhood
size of a domain is defined as the number of different partner
domains with which it co-occurs. More specifically, for each of the
25 known CM domains, we evaluated the empirical probability P
of observing an equal or smaller neighborhood size by chance (see
Methods). A high value of P suggests promiscuity, whereas low
values indicate selectivity.
The results of this analysis are summarized in Table 4. Dividing
the values of P into 3 ranges: P,0.2 (selective), P.0.8
(promiscuous) and 0.2#P#0.8 (background), we find that 4 of
25 CM domains (DOT1, SIR2, YEATS and Histone) show
consistently high selectivity across the 5 model organisms
considered here, and another 4 CM domains (Acetyltransf_1,
Hist_deacetyl, Helicase_C and Linker_histone) were selective in 4
of the 5 organisms.
In contrast, no domain was consistently promiscuous across all
organisms; BRCT and BAH qualify as promiscuous domains in 4
and 3 organisms, respectively. SNF2_N and Bromodomain were
promiscuous in worm and fly only. Interestingly, PHD was
promiscuous in worm but selective in mouse and human by the
above criteria. The P values for the remaining domains did not
deviate much from the background level in most of the organisms
(Table 4).
These results are in disagreement with those of a recent study in
which some CM domains, such as SET, PHD, Chromo, BRCT,
JmjC, TUDOR and Bromodomain, were found to be highly
promiscuous [48]. This discrepancy is likely due to various factors,
including a possible issue with factoring out the effect of domain
abundance in the previous study (see Discussion).
Prediction of CM genes based on domain composition
Using domain composition as a feature, our SVM-based
consensus procedure predicted a total of 379 candidate human
CM genes (Supplementary Table S4) coding for 329 proteins.
Figure 3. Abundance and combination partners of SET domains in yeast (y), worm (w), fly (f), mouse (m) and human (h) are shown
as an illustration of domain neighborhood expansion as a function of domain abundance. See Table 4 for SET domain abundance values
in each organism. The prefix in front of each domain name indicates the source organism. Nodes represent domains and links represent co-
occurrence relationship in a single protein. Size of the nodes is proportional to the number of domain-containing proteins in each genome, and
nodes are colored red, magenta and green to denote known CM domains, candidate CM domains and non-CM domains, respectively. The figures on
each edge indicate the numbers of proteins that contain the linked domain pairs. The thickness of edges is proportional to the Co-occurrence Score
of the linked domain pairs (See Materials and Methods for definition of Co-occurrence Score).
doi:10.1371/journal.pone.0014122.g003
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all, 234 (72%) of the predicted candidate CM genes contain at least
one of the 25 known CM domains, even though these domains were
not given higher weight than other domains in training the SVM
classifiers. Conversely, 19 (76%) of the 25 known CM domains
appear in at least one of the candidate CM genes. The most
frequently observed CM domains among these genes are: Histone,
PHD, Myb_DNA-binding, Acetyltransf_1, Helicase_C, Bromodo-
main, SFN2_N, SET and Chromo domains (Supplementary Figure
S3a). Although the Actin domain is not considered as a CM
domain, 26 Actin domain-containing genes were predicted to be
candidate CM gene. This is not too surprising given that several
chromatin remodeling complexes (Supplementary Table S3)
contain components that are annotated with this domain.
Of all our candidate CM genes, 21 are annotated as ‘‘chromatin
modification’’ or its child terms with the evidence code IEA
(Inferred from Electronical Annotation) in the GO catalog when
the annotations were initially downloaded. These genes were
excluded from our positive training set because they were not
supported by experimental evidence (IEA only). However, among
them, JMJD6, a histone arginine demethylase, and TERF2, a
telomeric repeat-binding factor, have been re-annotated recently
with supporting experimental evidence [49,50].
Several of our predicted CM genes have also been reported to
be involved in CM processes in very recent studies. For example,
the jumonji protein (JARID2) was found to form a chromatin
modifying complex that methylates H3K9 at the cyclin D1
promoter by recruiting G9a and GLP, two histone methyltrans-
ferases [51]. In another example, ALC1 (Amplified in Liver
Cancer 1), also known as CHD1L, was recently reported to
mediate poly(ADP-ribose)-dependent regulation of DNA repair by
binding to poly(ADP-ribosyl)-histone and stimulating nucleosome
sliding in an ATP-dependent manner [52].
For completeness, we compared our predictions with those
obtained using several publicly available automatic function
prediction methods [53,54], but the results were not very
informative, as most of these methods predict molecular or
biochemical functions, whereas our study predicts a relatively
specific function (‘‘chromatin modification’’) in the biological
process category.
Figure 4. A domain co-occurrence network for known CM domains and their combination partners in human. Nodes represent
domains and each link represents co-occurrence relationship of two domains in proteins. Size of the nodes is proportional to the number of domain-
containing proteins in each genome, and nodes are colored red, magenta and green, denoting known CM domains, candidate CM domains and non-
CM domains, respectively. The thickness of edges is proportional to the Co-occurrence Score for the linked domain pair (See Materials and Methods
for definition of Co-occurrence Score).
doi:10.1371/journal.pone.0014122.g004
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Domain Molucular Function Biological Process Co-occurring CM domain
Pescadillo_N Unkown cell proliferation BRCT
IMS damaged DNA binding domain (interpro) DNA repair BRCT
DDT predicted to be a DNA binding domain Unkown Bromodomain, PHD, MBD
PCAF_N a domain in the histone acetylase PCAF regulation of transcription,
DNA-dependent
Bromodomain, Acetyltransf_1
Pre-SET structural, stablize SET domain,
DNA binding
chromatin modification SET, Chromo, MBD
zf-C5HC2 predicted to bind DNA Unkown JmjC, JmjN, PHD
Chromo_shadow Required for Heterochromatin Spreading. Unkown Chromo
PLU-1 putative DNA/chromatin binding domain Unkown JmjC, JmjN, PHD
HAND putative DNA/nucleosome
binding domain
ATP-dependent chromatin
remodeling
SNF2_N, Helicase_C,
Myb_DNA_binding
SNase nucleic acid binding Unkown TUDOR
QLQ putative protein interaction domain regulation of transcription SNF2_N, Helicase_C, Bromodomain
SLIDE DNA binding chromatin remodeling SNF2_N, Helicase_C,
Myb_DNA_binding
NIF putative phosphatase Unkown BRCT
Rubis-subs-bind histone binding Unkown SET
RFC1 ATP binding DNA replication BRCT
TBP-binding TBP binding to suppress transcription Unkown Bromodomain
Bromo_TP predicted to bind DNA Unkown PHD
BRK Unkown Unkown SNF2_N, Helicase_C,
Bromodomain, Chromo
HARP Single-strand DNA-depedent ATPase chromatin modification SNF2_N, Helicase_C
zf-C2HC DNA binding zinc finger domain regulation of transcription,
DNA-dependent
MOZ_SAS, MBT
CBFD_NFYB_HMF sequence-specifid DNA binding Unkown Histone
HIRAN predicted to bind DNA, damaged DNA Unkown SNF2_N, Helicase_C
HSA predicted to bind DNA Unkown SNF2_N, Helicase_C, Bromodomain
ELM2 putative protein interaction domain Unkown BAH, Myb_DNA_binding
XRCC1_N specifically binds single-strand
break DNA
single strand break repair BRCT
TRF Telomeric DNA binding,
protein binding
telomere maintenance
via telomerase
Myb_DNA_binding
HNH Nucleic acid binding, endonuclease Unkown SNF2_N, Helicase_C
Nbs1_C protein-protein interaction domain Unkown BRCT
SANTA putative protein-protein interaction domain Unkown Myb_DNA_binding
Amino_oxidase catalytic domain of LSD1 Unkown SWIRM
SMN RNA binding mRNA processing,
spliceosome assembly
TUDOR
FYRC DNA binding Unkown PHD, SET
DUF1086 Unkown Unkown SNF2_N, Helicase_C, PHD, Chromo
SAND DNA binding Unkown Bromodomain, PHD
DUF1087 Unkown Unkown SNF2_N, Helicase_C, PHD, Chromo
FYRN DNA binding Unkown PHD, SET
ARID DNA binding Unkown JmjC, JmjN, PHD
zf-C2H2 DNA binding Unkown BAH, Myb_DNA_binding,
Bromodomain
53-BP1_Tudor mediates interaction with H3K79me Unkown BRCT
Sp100 Unkown Unkown Bromodomain, PHD
CHDNT DNA binding regulation of transcription SNF2_N, Helicase_C, PHD, Chromo
RecQ5 DNA helicase Unkown Helicase_C
Chromatin Modification
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zf-CXXC DNA binding Unkown JmjC, BAH, MBD, SET, PHD,
DNA_methylase
ZZ protein-protein interaction domain Unkown Myb_DNA_binding, Bromodomain
CHDCT2 DNA binding regulation of transcription SNF2_N, Helicase_C, PHD, Chromo
GATA DNA binding regulation of transcription, DNA-dependent Myb_DNA_binding, BAH
DSHCT ATP binding Unkown Helicase_C
The prediction of candidate CM domains was performed as described in the text. Function annotations are largely based on the literature and Pfam database. Co-
occurring CM domain: known CM domains that combine with a candidate CM domain in a single protein.
doi:10.1371/journal.pone.0014122.t003
Table 3. Cont.
Table 4. Promiscuity of known CM domains in 5 model organisms.
Yeast Worm Fly Mouse Human
Domain Ab Ap Sp P Ab Ap Sp P Ab Ap Sp P Ab Ap Sp P Ab Ap Sp P
SET 8 2 5.2 0.19 29 9 9.5 0.58 19 16 12.6 0.73 36 21 26.2 0.39 39 22 31.9 0.24
DOT1 1 0 0.5 0.00 6 0 1.6 0.00 1 0 0.5 0.00 1 1 0.5 0.12 1 1 0.6 0.13
JmjC 4 4 2.5 0.66 12 7 3.5 0.75 10 11 6.0 0.83 24 10 16.7 0.27 24 10 18.8 0.18
JmjN 3 3 1.8 0.55 2 5 0.5 0.27 4 6 2.1 0.65 10 5 6.2 0.46 9 5 6.2 0.45
PHD 15 9 10.3 0.48 25 19 8.0 0.93 39 36 28.0 0.78 81 41 60.8 0.17 87 43 71.5 0.06
Chromo 2 3 1.1 0.49 14 10 4.1 0.83 14 13 8.9 0.78 23 16 16.0 0.57 26 15 20.6 0.33
TUDOR NA NA NA NA 8 2 2.2 0.40 15 7 9.7 0.41 12 9 7.8 0.66 14 10 10.3 0.57
PWWP 2 0 1.2 0.00 1 0 0.2 0.00 9 8 5.3 0.73 23 17 15.9 0.62 20 17 15.4 0.64
MBT NA NA NA NA 2 0 0.5 0.00 3 3 1.5 0.45 9 4 5.6 0.41 9 4 6.2 0.36
MOZ_SAS 3 0 1.8 0.00 4 0 1.0 0.00 5 2 2.7 0.35 5 3 2.8 0.43 5 2 3.3 0.31
Acetyltransf_1 14 3 9.5 0.07 16 4 4.8 0.51 26 5 18.0 0.04 30 5 21.2 0.02 21 5 16.3 0.06
Hist_deacetyl 5 0 3.1 0.00 8 1 2.2 0.22 5 1 2.7 0.19 12 1 7.6 0.04 11 1 7.9 0.04
SIR2 5 1 3.1 0.17 4 0 1.0 0.00 5 0 2.7 0.00 7 0 4.2 0.00 8 0 5.5 0.00
Bromodomain 10 8 6.7 0.70 15 19 4.5 0.91 17 24 11.1 0.96 38 30 27.5 0.60 42 30 34.4 0.38
YEATS 3 0 1.8 0.00 2 0 0.5 0.00 3 0 1.5 0.00 4 0 2.3 0.00 4 0 2.5 0.00
BAH 5 4 3.2 0.64 4 8 1.0 0.48 6 11 3.3 0.82 10 15 6.2 0.91 11 14 7.8 0.87
BRCT 10 10 6.6 0.83 24 7 7.7 0.56 12 14 7.4 0.87 19 25 13.1 0.94 21 26 16.3 0.89
DNA_methylase NA NA NA NA NA NA NA NA 1 0 0.5 0.00 4 4 2.2 0.53 4 4 2.5 0.56
MBD NA NA NA NA 2 4 0.5 0.27 5 9 2.7 0.75 11 9 7.0 0.70 11 9 7.8 0.66
Helicase_C 79 23 55.5 0.00 82 32 30.0 0.56 77 40 56.3 0.15 106 55 79.4 0.14 114 56 92.0 0.05
SNF2_N 17 13 11.7 0.67 24 14 7.6 0.86 18 19 11.9 0.85 31 24 22.1 0.60 33 24 26.7 0.44
Myb_DNA-binding 15 7 10.3 0.31 13 6 3.8 0.70 16 10 10.5 0.55 38 17 27.6 0.23 37 18 30.3 0.17
SWIRM 5 2 3.1 0.36 3 2 0.7 0.30 3 2 1.5 0.37 5 4 2.9 0.54 5 4 3.3 0.53
Histone 11 1 7.4 0.03 74 0 26.9 0.00 98 5 71.5 0.00 91 6 67.9 0.00 86 6 70.7 0.00
Linker_histone 1 0 0.6 0.00 8 0 2.2 0.00 24 0 16.4 0.00 11 4 6.9 0.33 12 3 8.7 0.14
Promiscuity was estimated using a simulation procedure that allows for domain pair duplication (See the text for details). Ab: abundance, defined as the number of
proteins containing the domain in a genome. Ap: actual number of combination partners of a domain. Sp: number of combination partners of a domain obtained in
simulations. P: empirical probability of observing at most Ap combination partners during simulation of random combinations. A low P value indicates that a domain’s
actual combination partners are fewer than the results of most random simulations, and indicates that the domain is selective when combining with other domains. For
example, in human, the Ap, Sp and P values for the PHD domain are 43, 71.5 and 0.06, respectively; this means that probability P(Sp#Ap)=0.06 and, in other words, Ap
is less than 94% of simulated Sp values. Conversely, high P value indicates that a domain is promiscuous when combining with other domains. We considered domains
with P#0.2 as selective (marked as underlined in the table) and domains with P.0.8 as promiscuous (marked as bold in the table). Domains with P value in between 0.2
and 0.8 do not deviate from a random combination model. ‘‘NA’’ indicates that the domain is lacking in the organism.
doi:10.1371/journal.pone.0014122.t004
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Chromatin modification and related processes play a key role in
gene regulation in eukaryotes. But the molecular players and the
complex mechanisms involved remain largely unexplored, partic-
ularly in human and other metazoans. Our study produced
information that should help advance our knowledge of these
processes.
It identified additional proteins and domains in human that are
likely to carry out CM-related functions. 18 of these proteins are
now subjected to experimental verification in human cells, using
the MAPLE technology [55]. The present study also showed that
while most CM-domains involved in basic histone modification
processes are conserved across 5 model eukaryotes, the number of
genes/proteins containing each type of domain tends to increase
with the complexity of the organism, in line with the increased
spatial and temporal constraints of gene regulation in these
organisms.
Prediction of CM genes is a challenging task, in light of the fact
that CM is a relatively high level biological process, involving
proteins and domains with diverse biochemical activities and
molecular functions. Some molecular functions (e.g., histone lysine
acetyltransferase activity) of known CM domains are relatively
unique to CM, but many others (e.g., protein kinase activity and
DNA binding) are shared by a broad variety of different biological
processes. This fact compounded with our incomplete knowledge
of the ensemble of human CM-genes, contributes to a low
performance of our domain composition-based SVM classifier
when trained and cross-validated on a single version of the dataset.
To circumvent these problems and boost the reliability of the
classifier we used a consensus prediction approach, which requires
a gene to be classified as CM in multiple classification runs that use
different dataset definitions. This more stringent criterion appears
to reduce the number of false positives by nearly 20%. We
therefore consider the 379 candidate human CM genes (329
proteins) identified by this procedure to represent useful leads for
CM function, worthwhile to follow up by experimental analyses.
It is noteworthy that only 110 (30%) of these candidate genes
overlap with the list of 231 human genes recently predicted to have
CM-related function purely on the basis of orthology relationships
[21]. The 269 additional candidates not predicted by orthology
were identified here due to the fact that Pfam domain families tend
to include more distantly related family members than those
identified on the basis of strict orthology relationships. For
instance, the orthology-based approach identified 9 Bromodo-
main-containing human genes as potential CM genes based on
their orthology to yeast, worm and fly CM genes [21]. The
majority of these genes contain only the Bromodomain. In
addition to identifying all these genes, our domain-based approach
finds 11 other Bromodomain-containing CM genes, most of which
also contain other domains in different arrangements –architec-
tures- along the gene sequence (see Supplementary Table S6).
Genes with different domain architectures, cannot be detected as
orthologous by the customary reciprocal BLAST criteria [21,56].
Results of a systematic comparison of our domain-based SVM
predictions and those recently derived using orthology relation-
ships [21] are illustrated in Figure S3 of the Supplementary
Material. For 121 domains (including 16 known CM domains), we
predict more CM genes containing these domains than the
orthology-based method (See examples in Figure S3a). However,
the latter method outperforms the domain-based approach for 60
other domains, only one of which is a known CM domain.
Furthermore, the orthology-based method identifies 20 candidate
CM genes that completely lack Pfam domain annotations (Figure
S3b). A fraction of these candidate CM genes and others yet to be
discovered, may contain novel domain families, or code for
proteins with unstructured regions [57]. To identify more distantly
related CM-proteins of the latter type by bioinformatics methods,
will require methods capable of detecting distantly-related proteins
on the basis of sequence information alone [58].
Domain enrichment in known and predicted human CM
genes
A complementary view of the link between Pfam domains and
CM-related function can be obtained by estimating the extent to
which individual Pfam domains are enriched in human CM genes.
To this end we computed the log odds ratio (LOR) of the
conditional probabilities of observing a domain, given a CM gene
and a non-CM gene respectively (see Methods). This quantity was
computed with an extended set of 921 human CM genes,
including the 379 genes predicted here by the SVM procedure
(See Materials and Methods for the composition of this set).
Out of the total of 3469 Pfam domains currently annotated in
the human genome, only 366 (,10%) had an LOR above 0 on a
scale running from 26.7 to +6.6 and were thus considered as
occurring relatively more often in CM genes than non-CM genes
(Supplementary Table S5). In fact, 15 (60%) of the 25 domains in
our conservative initial set and 26 (55%) of the 47 candidate CM
domains identified here on the basis of their propensity to co-occur
with members of the initial set occur exclusively in CM proteins. It
was rewarding to see that all 25 CM domains in the initial set, as
well as 36 of the 47 candidate CM domains, are significantly
enriched in CM genes (Figure 5).
Of the remaining 11 domains that are not significantly enriched
in CM proteins (LOR,0), all but one (zf-C2H2) do not occur in
any of the CM proteins (either experimentally confirmed or
predicted) and only co-occur with either of the 3 CM domains,
Brct, Tudor or Helicase_C domains. We note however, that the
latter 3 domains are least enriched in CM proteins among the 25
domains of our initial set (see Supplementary Table S5), suggesting
in turn that they are less specifically related to chromatin
modification themselves. Consequently, domains that preferen-
tially associate with them are less reliable CM domain candidates.
Conversely, domains, such as Actin, zf-MIZ, MCM, Piwi, MH2,
which have high enrichment scores (.5) but are not currently
considered as CM-related domains or identified as candidate CM
domains by our co-occurrence analysis may actually deserve to be
considered as such.
This additional analysis confirms that our methods for
predicting CM genes and CM-related domains produce consistent
and converging results. These results are also largely consistent
with orthology based function predictions, in light of that 25%
(231/921) of the CM genes considered in the enrichment
calculations were predicted on the basis of orthology.
Promiscuity of CM domains
An interesting and potentially important finding of our study is
that the CM domains have a low propensity to co-occur with
many different domains, and are hence rarely promiscuous. CM
domains from all five model-organisms analyzed here, including
human, display this property, even though we also find that some
of these domains are markedly expanded and become increasingly
versatile in the process of evolution.
An opposite conclusion has been reached by another recent
computational analysis, which reports that CM domains, such as
SET, PHD, Chromo, BRCT, JmjC, TUDOR and Bromodomain,
are highly promiscuous [48]. A significant factor contributing to
this disagreement may be the approach used to normalize the
Chromatin Modification
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lished analysis used an information theoretic approach to measure
domain promiscuity. This approach adopted a very liberal
threshold for the measure of promiscuity (noted as p in ref 49)
so that domain abundance was hardly accounted for. In contrast,
our approach involves a random shuffling procedure, which has
domain abundance as a built-in constraint and therefore accounts
for it naturally. We also verified that it reproduces the power law
relationship between domain abundance and domain versatility
[13,25] (Supplementary Figure S1).
The low promiscuity of CM domains uncovered here, seems
consistent with the fact that CM proteins mostly operate in the
context of multi-protein complexes. These complexes are
moreover finely regulated at both the transcriptional and post-
transcriptional levels, to afford a high degree of specificity for their
targets, and as a result are probably subjected to strong negative
selection against promiscuous domain combinations.
DNA-binding domains in chromatin modification factors
A potentially very significant finding of our study is that CM
domains have a propensity to co-occur with DNA-binding
domains. Among the 25 known CM domains in our initial set,
only 4 (Hist_deactylase, SIR2, YEATS and Acetyltransf_1) do not
co-occur with DNA-binding domains. The remaining 21 domains
either co-occur with DNA-binding domains in at least one human
gene or have DNA-binding activity themselves.
For instance, in the multi-domain protein Sp140, a Bromodo-
main and a PHD domain co-occur with a SAND domain, which
binds a specific DNA motif (TTCG) [59]. In another example, the
ARID domain in the JmjC domain-containing histone H3K4
demethylase RBP2 binds to the DNA motif CCGCCC [60]. In the
ATP-dependent chromatin remodeling protein ISW2, which
contains the DNA-binding domains SNF2 and Helicase_C, two
additional DNA-binding domains (HAND and SLIDE domains)
are reportedly required to properly anchor and orient the ISW2
complex with respect to the nucleosomes and linker DNA [61].
While histonemodification-relateddomainshavebeenextensively
studied recently, the roles of DNA-binding domains in chromatin
modification have received little attention so far. For instance, it is
not clear what role the DNA-binding ARID domain plays in the
JmjC domain-containing histone H3K4 demethylase RBP2 [60].
Sequence-specific DNA-binding domains may recruit histone
modifying enzymes or remodeling proteins to the target nucleo-
somes. Conversely, domains that recognize specific histone modifi-
cations may be responsible for directing DNA-binding proteins to
their targets loci. A number of different scenarios may be envisaged:
1) if a histone modification-recognizing domains co-occurs with a
DNA-binding domain in transcription factors (eg, PHF20), it might
serve to link histone modification directly to gene regulation through
the concurrent binding to promoter DNA, and histone, thereby
enhancing binding specificity; 2) Simultaneous binding of DNA and
histone within the same nucleosome may facilitate or impede
chromatin remodeling by weakening or strengthening the 14
histone-DNA contacts, respectively; 3) Cooperative binding of
DNA and histone in different nucleosomes may lead to the
formation of long-range intra- or inter-chromosome chromatin
associations [62]. 4) Some of these DNA-binding domains may
actually bind non-coding RNAs, which have been recently shown to
associate with chromatin modifying complexes in human [63].
Further work is clearly needed to elucidate how chromatin
modification and DNA-binding activity are functionally coordi-
nated both spatially and temporally.
Figure 5. Distribution of log odds ratio (LOR) scores of Pfam domains in the human genome. LOR score measures enrichment of Pfam
domains in known and predicted human CM genes. The vast majority of Pfam domains score less than zero, and are thus not enriched or are even
under-represented in human CM genes. However, it is clear that the LOR scores of known CM domains and candidate CM domains skew towards the
higher end of the LOR spectrum, indicating that these domains are enriched in human CM genes.
doi:10.1371/journal.pone.0014122.g005
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Figure S1 The relationship between domain abundance and
domain neighborhood size in human genome. The logarithm of
domain neighborhood size (the number of distinct domains that
co-occur with a given domain in different proteins) is plotted
against the logarithm of domain abundance (the number of
proteins containing the given domain) in human. ‘‘log_nabe_hu-
man’’: the actual data obtained from human genome; ‘‘log_-
sim0_human’’: data obtained from simulation experiments in
which domains are randomly shuffled among genes in human
genome. ‘‘log_sim1_human’’: data obtained from simulation
experiments in which domains are randomly shuffled among
genes in human genome, and domain pair duplications were
introduced into the simulation procedure to mimic the effects of
duplication of multi-domain proteins. Refer to ‘‘Material and
Methods’’ in main text for details. A visual inspection indicates
that combination of domain pair duplications with random
shuffling provides a better approximation of the actual data than
random shuffling alone.
Found at: doi:10.1371/journal.pone.0014122.s001 (0.20 MB TIF)
Figure S2 Domain co-occurrence network for known CM
domains and their combination partners in yeast (a), worm (b),
and fly (c). Nodes represent domains and each link represents co-
occurrence relationship of two domains in proteins. Size of the
nodes is proportional to domain abundance in each genome, and
nodes are colored red, magenta and green, denoting known CM
domains, candidate CM domains and non-CM domains, respec-
tively. The thickness of edges is proportional to the Co-occurrence
Score for the linked domain pair (See Materials and Methods for
definition of Co-occurrence Score).
Found at: doi:10.1371/journal.pone.0014122.s002 (0.33 MB TIF)
Figure S3 (a) Pfam domains that appear more frequently in our
SVM predicted human CM genes than in those predicted by the
orthology-basedapproach.Onlythetop 36of121 suchdomainsare
shown. (b) Pfam domains that appear more frequently in CM genes
predicted by the orthology-based approach than in those predicted
by our SVM-based approach approach. The top 28 of 60 such
domains are shown. In both (a) and (b), ‘‘Exp_CM’’: experimentally
verified human CM genes (See SupplementaryTable 3). ‘‘svm_pre-
diction’’: CM genes predicted by our SVM-based approach only.
‘‘orth_prediction’’: CM genes predicted by orthology-based
approach only. ‘‘common_prediction’’: CM genes predicted by
both approaches. ‘‘_Domain_less’’ on the x-axis of panel (b) denotes
CM genes that lack Pfam domain annotations. Note that the
orthology-based approach is able to predict CM genes in the
absence of Pfam domain annotations, while our SVM-based
approach cannot.
Found at: doi:10.1371/journal.pone.0014122.s003 (0.19 MB TIF)
Table S1 Number of protein-coding genes and number of
unique Pfam-A domains in Yeast, Worm, Fly, Mouse and Human
genomes downloaded from Ensembl v.53.
Found at: doi:10.1371/journal.pone.0014122.s004 (0.02 MB
XLS)
Table S2 List of experimentally verified CM genes in the
budding yeast, S. cerevisiae. ‘‘-’’ in the ‘‘GO annotation’’ column
and the ‘‘CYC2008 complex’’ column indicates the gene is not
annotated with ‘‘Chromatin modification’’ in the Gene Ontology
database and not found in any of the CYC2008 complexes,
respectively.
Found at: doi:10.1371/journal.pone.0014122.s005 (0.08 MB
XLS)
Table S3 List of experimentally verified CM genes in human.
Again, ‘‘-’’ indicates annotation for the gene is missing. In the
‘‘CORUM complex’’ column, each complex name is followed by
a PubMed ID, providing supporting experimental evidence for the
complex.
Found at: doi:10.1371/journal.pone.0014122.s006 (0.19 MB
XLS)
Table S4 List of CM genes predicted with our SVM-based
approach in human. ‘‘Pfam ID’’ column provides the name of
Pfam domains contained in a gene. The ‘‘mean SVM_score’’
column is the average of SVM scores of predictions (SVM
score.0 means the gene is predicted as a CM gene, otherwise, it is
predicted as a non-CM gene). The ‘‘SVM_std’’ column is the
standard deviation of the mean. The ‘‘Frequency of prediction’’
column indicates how many times the gene is randomly selected
for prediction. The value of this column should be around 200, but
due to randomization, some genes are picked more frequently
than other genes. The ‘‘P_value’’ column provides the probability
the SVM score is #0, which indicates that gene is classified as a
non-CM gene, assuming normal distribution for the SVM scores.
This list of 379 genes is divided into two sections. The first section,
marked in green, contains genes coding for the 329 non-redundant
proteins (including 61 proteins that belong to the actin family and
the histone family). The second section, marked in blue, lists genes
coding for proteins which have been already identified as known
or candidate CM proteins archived in the Supplementary Table 3
or in the first section of this table, respectively.
Found at: doi:10.1371/journal.pone.0014122.s007 (0.69 MB
XLS)
Table S5 Enrichment of Pfam domains in human CM genes.
The ‘‘# in CM gene’’ and the ‘‘# in non-CM gene’’ denote the
number of CM genes and non-CM genes containing the particular
domain, respectively. LOR: log odds ratio. High LOR indicates
the domain is highly enriched in CM genes. The 25 known CM
domains and 47 predicted CM domains are highlighted and their
LOR values are re-organized in separate sections.
Found at: doi:10.1371/journal.pone.0014122.s008 (0.42 MB
XLS)
Table S6 Bromodomain-containing CM genes predicted by
SVM-based and/or orthology-based approaches.
Found at: doi:10.1371/journal.pone.0014122.s009 (0.02 MB
XLS)
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